Skip to main content
Caplight Logo









Zhimeng Biopharma

Zhimeng Biopharma

Private
ShanghaiHealthcare & Life Scienceshttp://core-biopharma.com/

Last Round

Series B

Nov 8, 2021

Total Funding Raised

$98M

Company Overview

Zhimeng Biopharma is a biopharmaceutical company that develops innovative small-molecule therapeutics for the treatment of chronic hepatitis B and neurological disorders.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biotechnologydrug discoverysmall-molecule therapeuticschronic hepatitis BCHBCNS disordersamyotrophic lateral sclerosisALSclinical-stage biotechcapsid assembly modulatorspotassium channel openerbiopharma licensingdrug pipelineclinical trialsbiotech startup

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Zhimeng Biopharma Comparables

Compare Zhimeng Biopharma with similar companies based on industry and business-model similarity.

Zhimeng Biopharma comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
NeuShen Therapeutics
78%
Shanghai Hepu Pharmaceutical Co., Ltd.
74%
Brii Biosciences
74%

Zhimeng Biopharma Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BNov 8, 2021
Series ANov 6, 2020
Pre SeedNov 11, 2019

Zhimeng Biopharma Investors

Notable investors and investment history

Zhimeng Biopharma investors
InvestorRounds
Photon FundSeries A
SDIC Unity CapitalSeries A
中南创投基金Series A
Shenzhen Dachen Caizhi Venture Capital ManagementSeries B
Trinity Innovation FundSeries A
Advantech CapitalSeries B
Lake CapitalSeries A, Pre Seed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 5, 2026

    Monthly visitors increased 112% MoM.

Zhimeng Biopharma Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Zhimeng Biopharma Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Zhimeng Biopharma's valuation, stock price, and market status.

Firmographic Details

HeadquartersShanghai
Employee Range7
Year Founded2017
Last FundingNov 8, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?